Trials / Unknown
UnknownNCT02832297
Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 318 (estimated)
- Sponsor
- Crescendo Bioscience · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this 12-month multi-center prospective, site-randomized, two-arm trial, approximately 318 biologic-naïve subjects with RA who are candidates for treatment intensification due to inadequate response to MTX monotherapy will be enrolled at up to 60 study sites.
Detailed description
To determine whether a strategy of Vectra DA guided care (Arm A), compared with usual care (Arm B), achieves non-inferior clinical outcomes while reducing the cost of treatment in patients with active RA and an inadequate response to MTX monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Vectra DA | |
| OTHER | Usual Care |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2016-07-14
- Last updated
- 2018-07-30
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02832297. Inclusion in this directory is not an endorsement.